• AbbVie, Tizona Collaborating on Development of New CD39-targeted Immunotherapies
  • Scientists Discover FGL1, A Key Blocker of Immune Response Against Certain Cancers
  • Keytruda Receives Five New Approvals in Japan, Including 3 Expanded Uses for Lung Cancer
  • Phase 3 Trial Explores Cabometyx-Tecentriq Combo Therapy in Advanced Liver Cancer
  • Certain Brain Tumors May Respond to Immunotherapies, Other Approved Treatments
  • Obesity Plays Paradoxical Role in Cancer, Study Shows
  • Top 10 Immuno-Oncology Stories of 2018
  • Celyad’s Donor-derived CAR T-cell Therapy Begins Testing in Colorectal Cancer
  • Keytruda Seen as ‘Kinder’ and Superior to Standard Therapies for Advanced Head and Neck Cancer Patients in Phase 3 Trial
  • Phase 3 Trial to Test GPS Vaccine as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients
  • AMG 330 Immunotherapy Shows Promise in Relapsed or Refractory Acute Myeloid Leukemia
  • Imfinzi Falls Short in Prolonging Overall Survival of Metastatic NSCLC Patients, Phase 3 Trial Shows